Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 17, 2021 - Issue
Submit an article Journal homepage
384
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain

Benjamin KearnsSchool of Health and Related Research, The University of Sheffield, Sheffield, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7730-668XView further author information
ORCID Icon,
Katy CooperSchool of Health and Related Research, The University of Sheffield, Sheffield, UKORCID Iconhttps://orcid.org/0000-0002-7702-8103View further author information
ORCID Icon,
Anna CantrellSchool of Health and Related Research, The University of Sheffield, Sheffield, UKORCID Iconhttps://orcid.org/0000-0003-0040-9853View further author information
ORCID Icon &
Chloe ThomasSchool of Health and Related Research, The University of Sheffield, Sheffield, UKORCID Iconhttps://orcid.org/0000-0001-8704-3262View further author information
ORCID Icon
Pages 125-137 | Published online: 20 Jan 2021

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anna Kotzeva, Deepali Mittal, Supriya Desai, Davneet Judge & Kunal Samanta. (2023) Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. Journal of Medical Economics 26:1, pages 70-83.
Read now
Jeremy Mills. (2022) Are Nurses Prescribing Lumateperone (Caplyta)?. Issues in Mental Health Nursing 43:1, pages 91-93.
Read now

Articles from other publishers (7)

I. V. Oleichik, T. I. Shishkovskaya, P. A. Baranov & I. Yu. Nikiforova. (2022) Features of Clinical Use of Brexpiprazole, the New Atypical Antipsychotic of the Third Generation: Experience and Perspectives. Psikhiatriya 20:3, pages 134-142.
Crossref
John M. Kane. (2022) A New Treatment Paradigm. Journal of Clinical Psychopharmacology 42:5, pages S1-S13.
Crossref
Amy Dymond, Daniela Afonso & Will Green. (2022) Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom. BMC Health Services Research 22:1.
Crossref
Benjamin Kearns, Katy Cooper, Martin Orr, Munira Essat, Jean Hamilton & Anna Cantrell. (2022) The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. Neuropsychiatric Disease and Treatment Volume 18, pages 1133-1143.
Crossref
Ya-Hsuan Wang, Chia-Yu Liu, Yu-Ning Her, Hung-Hsi Wu, Chia-Yi Yao & Tien-Yu Chen. (2022) Lurasidone Successfully Reversed Clozapine-Induced Type 2 Diabetes Mellitus and Hypertriglyceridemia in a Patient With Schizophrenia. American Journal of Therapeutics Publish Ahead of Print.
Crossref
Matej Ľupták, Zdeněk Fišar & Jana Hroudová. (2021) Effect of Novel Antipsychotics on Energy Metabolism — In Vitro Study in Pig Brain Mitochondria. Molecular Neurobiology 58:11, pages 5548-5563.
Crossref
Alveena Batool Syed & James Robert Brašić. (2021) The role of lumateperone in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology 11, pages 204512532110340.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.